Oragenics OGEN Corporate Presentation January 2024

Oragenics presents its strategic focus on nasal drug delivery technologies and the development of ONP-002, a first-in-class neurosteroid for treating moderate to severe concussion. The company outlines its pipeline expansion, Phase IIa clinical trial timeline starting in Q2 2024, and the significant market opportunity in the nasal drug delivery space projected to reach $112 billion by 2030.